Key Insights

Highlights

Treatment Research

1 treatments under study, led by Autologous Bone Marrowderived Mononuclear Cells

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2/3 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Research Network

Common Treatments

  • Autologous Bone Marrowderived Mononuclear Cells1

Active Sponsors

  • Institute for Clinical and Experimental Medicine1

Related Conditions

  • Lower Limb Ischemia1

Activity Timeline